| Myriad and the Patent-Eligibility of Genetic Inventions: What’s the Matter Under 35 U.S.C. § 101? |
Intellectual Property & Technology Law Journal |
2011 |
| Implication for Biotechnology Enterprises and Investors as District Court Invalidates Cancer Gene Patents |
Prior Firm Client Alert |
2010 |
| In re Bilski: Federal Circuit Affirms Patent Office in Narrowing Scope of Patentable Subject Matter |
Prior Firm Client Alert |
2008 |
| Taking a Global View of a Life Sciences Company’s Patent Positio |
The Journal of BioLaw & Business |
2004 |
| Federal Circuit Holds That in Determining Whether Infringement of a Patent Was Willful, Clients Can Now Assert Their Attorney-Client Privilege Without Risk of an Adverse Inference That a Legal Opinion Was Negative |
Prior Firm Client Alert |
2004 |
| Gene Patents: Testing the Limits |
Intellectual Property Observer |
2002 |
| E-Rights: Wagging the Electronic Tale |
The Journal of BioLaw & Business |
2002 |
| Navigating the Complicated Terrain of Joint Ownership |
Intellectual Property Observer |
2001 |
| Production of Live Offspring with Predicted Genotypes Using PCR-RFLP Analysis of Polar Bodies From Mouse Oocytes |
Molecular Reproductive Development |
1995 |
| The Effect of Ca2+ Channel Antagonists (Cadmium, ω-Conotoxin, GIVA, and Nitrendipine) on the Release of Angiotensin II from Fetal Rat Brain Cell Culture In Vitro |
Neuroscience Letters |
1991 |
| The Release of Angiotensin Following Isoproternol, Cholera Toxin, Forskolin and Phorbol Ester Stimulation of Fetal Rat Brain in Culture |
Neuroscience Abstracts |
1990 |
| The Role and Potential Interaction of Adenylate Cyclase, Protein Kinase C, and Calmodulin on Angiotensin Release from Dissociated Brain Cell Cultures |
Society for Neuroscience Abstracts |
1990 |